Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MAS825 in Healthy Volunteers
NCT04665154Phase 1Completed
- Sponsor
- Novartis
- Start
- Jun 2019
- Primary completion
- Aug 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of MAS825 in autoinflammatory diseases (SAIDs) (4 arms), sponsored by Novartis. Primary endpoint: Number of Adverse Events. Started Jun 2019; status: completed.
02
Drugs
MAS825
03
Conditions
autoinflammatory diseases (SAIDs)
Beyond the preview
Go deeper on NCT04665154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665154.